

Global Autologous iPSC-Derived Cell Therapy Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GDAF0B398D3AEN.html>

Date: October 2026

Pages: 89

Price: US\$ 3,660.00 (Single User License)

ID: GDAF0B398D3AEN

Abstracts

The global Autologous iPSC-Derived Cell Therapy market size is predicted to grow from US\$ 44.02 million in 2025 to US\$ 350 million in 2032; it is expected to grow at a CAGR of 33.2% from 2026 to 2032.

Autologous iPSC-Derived Cell Therapies are personalized regenerative medicine products manufactured by reprogramming a patient's own somatic cells, such as peripheral blood cells or skin fibroblasts, into induced pluripotent stem cells (iPSCs), followed by directed differentiation into functional cell types including dopaminergic neural progenitor cells, retinal pigment epithelial (RPE) cells, cardiovascular cells, islet-like cells, or immune cells. These differentiated cells are subsequently transplanted or infused back into the same patient. This therapeutic approach emphasizes immune compatibility, high cell purity, genomic stability, minimal tumorigenic risk, GMP-compliant closed manufacturing processes, and complete product traceability. It is primarily being developed for neurodegenerative diseases, retinal degenerative disorders, ischemic cardiovascular diseases, metabolic and endocrine disorders, and tissue regeneration applications. The overall gross margin is approximately 52%.

Demand for autologous iPSC-derived cell therapies is primarily driven by the significant unmet medical needs in degenerative diseases where conventional drug therapies can only alleviate symptoms rather than restore lost tissue function. Diseases such as Parkinson's disease, retinal degeneration, myocardial injury, and pancreatic islet dysfunction all have well-established rationales for cell replacement therapy. Because autologous cells are immunologically matched to the patient, this approach can substantially reduce the risk of immune rejection and minimize the need for long-term immunosuppressive therapy, making it particularly attractive for applications requiring durable cell survival and functional integration.

The key challenge for industrial development is transforming patient-specific cell manufacturing from laboratory-scale processes into standardized, reproducible, and GMP-compliant commercial production. Companies are building integrated platforms covering peripheral blood or skin sample collection, iPSC line establishment, directed differentiation, residual undifferentiated cell elimination, genomic stability testing, and closed, automated manufacturing systems. Future competitiveness will depend not only on clinical outcomes in individual indications but also on manufacturing turnaround time, production success rate, quality control standards, and optimized cell delivery procedures.

Regionally, the United States, China, Japan, and South Korea are leading the development of autologous iPSC-derived therapies. Ongoing clinical studies and regulatory engagement are expected to continue driving demand for early-stage manufacturing services, CDMO partnerships, and automated cell production equipment. Despite challenges including high manufacturing costs, lengthy production timelines, patient-to-patient variability, and stringent long-term follow-up requirements, successful demonstration of safety and functional efficacy in key indications could enable autologous iPSC platforms to expand from a limited number of high-value indications into a broad range of personalized regenerative medicine products.

Report Scope

LPI (LP Information)' newest research report, the “Autologous iPSC-Derived Cell Therapy Industry Forecast” looks at past sales and reviews total world Autologous iPSC-Derived Cell Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected Autologous iPSC-Derived Cell Therapy sales for 2026 through 2032. With Autologous iPSC-Derived Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Autologous iPSC-Derived Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global Autologous iPSC-Derived Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Autologous iPSC-Derived Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Autologous iPSC-Derived Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Autologous iPSC-Derived Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Autologous iPSC-Derived Cell Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Autologous iPSC-Derived Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:

- Autologous iPSC-Derived Neural Cell Therapy
- Autologous iPSC-Derived Retinal Cell Therapy
- Autologous iPSC-Derived Cardiovascular Cell Therapy
- Autologous iPSC-Derived Islet Cell Therapy
- Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
- Autologous iPSC-Derived Immune Cell Therapy
- Other Autologous iPSC-Derived Cell Therapy

Segmentation by Somatic Cell Source:

- Peripheral Blood-Derived
- Skin Fibroblast-Derived
- Urine Cell-Derived

Dental Pulp Cell-Derived

Other Somatic Cell-Derived

Segmentation by Delivery Form:

Cell Suspension for Injection

Cell Sheet

Scaffold-Seeded Cell Patch

Encapsulated Cell Implant

Tissue Aggregate or Organoid Graft

Other Delivery Form

Segmentation by Development Stage:

Preclinical Candidate

IND-Enabling Candidate

Phase I Clinical Product

Phase II Clinical Product

Pivotal or Registration Stage Product

Approved Product

Segmentation by Application:

Neurodegenerative Diseases

Retinal Degenerative Diseases

Cardiovascular Ischemic Diseases

Metabolic and Endocrine Diseases

Immune and Inflammatory Diseases

Other Regenerative Applications

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Aspen Neuroscience

UniXell Biotechnology

Oryon Cell Therapies

Cellio Therapeutics

Cellino

Kadis Bio

HeartWorks

iCamuno Biotherapeutics

Shize Biomedicine

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Autologous iPSC-Derived Cell Therapy Market Size (2021-2032)
 - 2.1.2 Autologous iPSC-Derived Cell Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Autologous iPSC-Derived Cell Therapy by Country/Region (2021, 2025 & 2032)
- 2.2 Autologous iPSC-Derived Cell Therapy Segment by Type
 - 2.2.1 Autologous iPSC-Derived Neural Cell Therapy
 - 2.2.2 Autologous iPSC-Derived Retinal Cell Therapy
 - 2.2.3 Autologous iPSC-Derived Cardiovascular Cell Therapy
 - 2.2.4 Autologous iPSC-Derived Islet Cell Therapy
 - 2.2.5 Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
 - 2.2.6 Autologous iPSC-Derived Immune Cell Therapy
 - 2.2.7 Other Autologous iPSC-Derived Cell Therapy
 - 2.2.8 Autologous iPSC-Derived Cell Therapy Market Size by Type
 - 2.2.8.1 Autologous iPSC-Derived Cell Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.8.2 Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2026)
- 2.3 Autologous iPSC-Derived Cell Therapy Segment by Somatic Cell Source
 - 2.3.1 Peripheral Blood-Derived
 - 2.3.2 Skin Fibroblast-Derived
 - 2.3.3 Urine Cell-Derived
 - 2.3.4 Dental Pulp Cell-Derived

2.3.5 Other Somatic Cell-Derived

2.3.6 Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source

2.3.6.1 Autologous iPSC-Derived Cell Therapy Market Size CAGR by Somatic Cell Source (2021 VS 2025 VS 2032)

2.3.6.2 Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source (2021-2026)

2.4 Autologous iPSC-Derived Cell Therapy Segment by Delivery Form

2.4.1 Cell Suspension for Injection

2.4.2 Cell Sheet

2.4.3 Scaffold-Seeded Cell Patch

2.4.4 Encapsulated Cell Implant

2.4.5 Tissue Aggregate or Organoid Graft

2.4.6 Other Delivery Form

2.4.7 Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form

2.4.7.1 Autologous iPSC-Derived Cell Therapy Market Size CAGR by Delivery Form (2021 VS 2025 VS 2032)

2.4.7.2 Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form (2021-2026)

2.5 Autologous iPSC-Derived Cell Therapy Segment by Development Stage

2.5.1 Preclinical Candidate

2.5.2 IND-Enabling Candidate

2.5.3 Phase I Clinical Product

2.5.4 Phase II Clinical Product

2.5.5 Pivotal or Registration Stage Product

2.5.6 Approved Product

2.5.7 Autologous iPSC-Derived Cell Therapy Market Size by Development Stage

2.5.7.1 Autologous iPSC-Derived Cell Therapy Market Size CAGR by Development Stage (2021 VS 2025 VS 2032)

2.5.7.2 Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2026)

2.6 Autologous iPSC-Derived Cell Therapy Segment by Application

2.6.1 Neurodegenerative Diseases

2.6.2 Retinal Degenerative Diseases

2.6.3 Cardiovascular Ischemic Diseases

2.6.4 Metabolic and Endocrine Diseases

2.6.5 Immune and Inflammatory Diseases

2.6.6 Other Regenerative Applications

2.6.7 Autologous iPSC-Derived Cell Therapy Market Size by Application

2.6.7.1 Autologous iPSC-Derived Cell Therapy Market Size CAGR by Application

(2021 VS 2025 VS 2032)

2.6.7.2 Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2026)

3 AUTOLOGOUS IPSC-DERIVED CELL THERAPY MARKET SIZE BY PLAYER

3.1 Autologous iPSC-Derived Cell Therapy Market Size Market Share by Player

3.1.1 Global Autologous iPSC-Derived Cell Therapy Revenue by Player (2021-2026)

3.1.2 Global Autologous iPSC-Derived Cell Therapy Revenue Market Share by Player (2021-2026)

3.2 Global Autologous iPSC-Derived Cell Therapy Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 AUTOLOGOUS IPSC-DERIVED CELL THERAPY BY REGION

4.1 Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2026)

4.2 Global Autologous iPSC-Derived Cell Therapy Annual Revenue by Country/Region (2021-2026)

4.3 Americas Autologous iPSC-Derived Cell Therapy Market Size Growth (2021-2026)

4.4 APAC Autologous iPSC-Derived Cell Therapy Market Size Growth (2021-2026)

4.5 Europe Autologous iPSC-Derived Cell Therapy Market Size Growth (2021-2026)

4.6 Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Autologous iPSC-Derived Cell Therapy Market Size by Country (2021-2026)

5.2 Americas Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026)

5.3 Americas Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2026)

6.2 APAC Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026)

6.3 APAC Autologous iPSC-Derived Cell Therapy Market Size by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Autologous iPSC-Derived Cell Therapy Market Size by Country (2021-2026)

7.2 Europe Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026)

7.3 Europe Autologous iPSC-Derived Cell Therapy Market Size by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Autologous iPSC-Derived Cell Therapy by Region (2021-2026)

8.2 Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size by Type
(2021-2026)

8.3 Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size by
Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL AUTOLOGOUS iPSC-DERIVED CELL THERAPY MARKET FORECAST

10.1 Global Autologous iPSC-Derived Cell Therapy Forecast by Region (2027-2032)

10.1.1 Global Autologous iPSC-Derived Cell Therapy Forecast by Region (2027-2032)

10.1.2 Americas Autologous iPSC-Derived Cell Therapy Forecast

10.1.3 APAC Autologous iPSC-Derived Cell Therapy Forecast

10.1.4 Europe Autologous iPSC-Derived Cell Therapy Forecast

10.1.5 Middle East & Africa Autologous iPSC-Derived Cell Therapy Forecast

10.2 Americas Autologous iPSC-Derived Cell Therapy Forecast by Country (2027-2032)

10.2.1 United States Market Autologous iPSC-Derived Cell Therapy Forecast

10.2.2 Canada Market Autologous iPSC-Derived Cell Therapy Forecast

10.2.3 Mexico Market Autologous iPSC-Derived Cell Therapy Forecast

10.2.4 Brazil Market Autologous iPSC-Derived Cell Therapy Forecast

10.3 APAC Autologous iPSC-Derived Cell Therapy Forecast by Region (2027-2032)

10.3.1 China Autologous iPSC-Derived Cell Therapy Market Forecast

10.3.2 Japan Market Autologous iPSC-Derived Cell Therapy Forecast

10.3.3 Korea Market Autologous iPSC-Derived Cell Therapy Forecast

10.3.4 Southeast Asia Market Autologous iPSC-Derived Cell Therapy Forecast

10.3.5 India Market Autologous iPSC-Derived Cell Therapy Forecast

10.3.6 Australia Market Autologous iPSC-Derived Cell Therapy Forecast

10.4 Europe Autologous iPSC-Derived Cell Therapy Forecast by Country (2027-2032)

10.4.1 Germany Market Autologous iPSC-Derived Cell Therapy Forecast

10.4.2 France Market Autologous iPSC-Derived Cell Therapy Forecast

10.4.3 UK Market Autologous iPSC-Derived Cell Therapy Forecast

10.4.4 Italy Market Autologous iPSC-Derived Cell Therapy Forecast

10.4.5 Russia Market Autologous iPSC-Derived Cell Therapy Forecast

10.5 Middle East & Africa Autologous iPSC-Derived Cell Therapy Forecast by Region (2027-2032)

10.5.1 Egypt Market Autologous iPSC-Derived Cell Therapy Forecast

10.5.2 South Africa Market Autologous iPSC-Derived Cell Therapy Forecast

10.5.3 Israel Market Autologous iPSC-Derived Cell Therapy Forecast

10.5.4 Turkey Market Autologous iPSC-Derived Cell Therapy Forecast

10.6 Global Autologous iPSC-Derived Cell Therapy Forecast by Type (2027-2032)

10.7 Global Autologous iPSC-Derived Cell Therapy Forecast by Application
(2027-2032)

10.7.1 GCC Countries Market Autologous iPSC-Derived Cell Therapy Forecast

11 KEY PLAYERS ANALYSIS

11.1 Aspen Neuroscience

11.1.1 Aspen Neuroscience Company Information

11.1.2 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product Offered

11.1.3 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue, Gross
Margin and Market Share (2021-2026)

11.1.4 Aspen Neuroscience Main Business Overview

11.1.5 Aspen Neuroscience Latest Developments

11.2 UniXell Biotechnology

11.2.1 UniXell Biotechnology Company Information

11.2.2 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product Offered

11.2.3 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue, Gross
Margin and Market Share (2021-2026)

11.2.4 UniXell Biotechnology Main Business Overview

11.2.5 UniXell Biotechnology Latest Developments

11.3 Oryon Cell Therapies

11.3.1 Oryon Cell Therapies Company Information

11.3.2 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product Offered

11.3.3 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue, Gross
Margin and Market Share (2021-2026)

11.3.4 Oryon Cell Therapies Main Business Overview

11.3.5 Oryon Cell Therapies Latest Developments

11.4 Cellio Therapeutics

11.4.1 Cellio Therapeutics Company Information

11.4.2 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product Offered

11.4.3 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross
Margin and Market Share (2021-2026)

11.4.4 Cellio Therapeutics Main Business Overview

11.4.5 Cellio Therapeutics Latest Developments

11.5 Cellino

11.5.1 Cellino Company Information

11.5.2 Cellino Autologous iPSC-Derived Cell Therapy Product Offered

11.5.3 Cellino Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and

Market Share (2021-2026)

11.5.4 Cellino Main Business Overview

11.5.5 Cellino Latest Developments

11.6 Kadis Bio

11.6.1 Kadis Bio Company Information

11.6.2 Kadis Bio Autologous iPSC-Derived Cell Therapy Product Offered

11.6.3 Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and

Market Share (2021-2026)

11.6.4 Kadis Bio Main Business Overview

11.6.5 Kadis Bio Latest Developments

11.7 HeartWorks

11.7.1 HeartWorks Company Information

11.7.2 HeartWorks Autologous iPSC-Derived Cell Therapy Product Offered

11.7.3 HeartWorks Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin

and Market Share (2021-2026)

11.7.4 HeartWorks Main Business Overview

11.7.5 HeartWorks Latest Developments

11.8 iCamuno Biotherapeutics

11.8.1 iCamuno Biotherapeutics Company Information

11.8.2 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product Offered

11.8.3 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

11.8.4 iCamuno Biotherapeutics Main Business Overview

11.8.5 iCamuno Biotherapeutics Latest Developments

11.9 Shize Biomedicine

11.9.1 Shize Biomedicine Company Information

11.9.2 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product Offered

11.9.3 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

11.9.4 Shize Biomedicine Main Business Overview

11.9.5 Shize Biomedicine Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Autologous iPSC-Derived Cell Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Autologous iPSC-Derived Cell Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Autologous iPSC-Derived Neural Cell Therapy

Table 4. Major Players of Autologous iPSC-Derived Retinal Cell Therapy

Table 5. Major Players of Autologous iPSC-Derived Cardiovascular Cell Therapy

Table 6. Major Players of Autologous iPSC-Derived Islet Cell Therapy

Table 7. Major Players of Autologous iPSC-Derived Mesenchymal-Like Cell Therapy

Table 8. Major Players of Autologous iPSC-Derived Immune Cell Therapy

Table 9. Major Players of Other Autologous iPSC-Derived Cell Therapy

Table 10. Autologous iPSC-Derived Cell Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 11. Global Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026) & (\$ millions)

Table 12. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2026)

Table 13. Major Players of Peripheral Blood-Derived

Table 14. Major Players of Skin Fibroblast-Derived

Table 15. Major Players of Urine Cell-Derived

Table 16. Major Players of Dental Pulp Cell-Derived

Table 17. Major Players of Other Somatic Cell-Derived

Table 18. Autologous iPSC-Derived Cell Therapy Market Size CAGR by Somatic Cell Source (2021 VS 2025 VS 2032) & (\$ millions)

Table 19. Global Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2021-2026) & (\$ millions)

Table 20. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source (2021-2026)

Table 21. Major Players of Cell Suspension for Injection

Table 22. Major Players of Cell Sheet

Table 23. Major Players of Scaffold-Seeded Cell Patch

Table 24. Major Players of Encapsulated Cell Implant

Table 25. Major Players of Tissue Aggregate or Organoid Graft

Table 26. Major Players of Other Delivery Form

Table 27. Autologous iPSC-Derived Cell Therapy Market Size CAGR by Delivery Form

(2021 VS 2025 VS 2032) & (\$ millions)

Table 28. Global Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2021-2026) & (\$ millions)

Table 29. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form (2021-2026)

Table 30. Major Players of Preclinical Candidate

Table 31. Major Players of IND-Enabling Candidate

Table 32. Major Players of Phase I Clinical Product

Table 33. Major Players of Phase II Clinical Product

Table 34. Major Players of Pivotal or Registration Stage Product

Table 35. Major Players of Approved Product

Table 36. Autologous iPSC-Derived Cell Therapy Market Size CAGR by Development Stage (2021 VS 2025 VS 2032) & (\$ millions)

Table 37. Global Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2021-2026) & (\$ millions)

Table 38. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2026)

Table 39. Autologous iPSC-Derived Cell Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 40. Global Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (\$ millions)

Table 41. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2026)

Table 42. Global Autologous iPSC-Derived Cell Therapy Revenue by Player (2021-2026) & (\$ millions)

Table 43. Global Autologous iPSC-Derived Cell Therapy Revenue Market Share by Player (2021-2026)

Table 44. Autologous iPSC-Derived Cell Therapy Key Players Head office and Products Offered

Table 45. Autologous iPSC-Derived Cell Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 46. New Products and Potential Entrants

Table 47. Mergers & Acquisitions, Expansion

Table 48. Global Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2026) & (\$ millions)

Table 49. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Region (2021-2026)

Table 50. Global Autologous iPSC-Derived Cell Therapy Revenue by Country/Region (2021-2026) & (\$ millions)

Table 51. Global Autologous iPSC-Derived Cell Therapy Revenue Market Share by Country/Region (2021-2026)

Table 52. Americas Autologous iPSC-Derived Cell Therapy Market Size by Country (2021-2026) & (\$ millions)

Table 53. Americas Autologous iPSC-Derived Cell Therapy Market Size Market Share by Country (2021-2026)

Table 54. Americas Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026) & (\$ millions)

Table 55. Americas Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2026)

Table 56. Americas Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (\$ millions)

Table 57. Americas Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2026)

Table 58. APAC Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2026) & (\$ millions)

Table 59. APAC Autologous iPSC-Derived Cell Therapy Market Size Market Share by Region (2021-2026)

Table 60. APAC Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026) & (\$ millions)

Table 61. APAC Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (\$ millions)

Table 62. Europe Autologous iPSC-Derived Cell Therapy Market Size by Country (2021-2026) & (\$ millions)

Table 63. Europe Autologous iPSC-Derived Cell Therapy Market Size Market Share by Country (2021-2026)

Table 64. Europe Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026) & (\$ millions)

Table 65. Europe Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (\$ millions)

Table 66. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2026) & (\$ millions)

Table 67. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026) & (\$ millions)

Table 68. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (\$ millions)

Table 69. Key Market Drivers & Growth Opportunities of Autologous iPSC-Derived Cell Therapy

Table 70. Key Market Challenges & Risks of Autologous iPSC-Derived Cell Therapy

Table 71. Key Industry Trends of Autologous iPSC-Derived Cell Therapy
Table 72. Global Autologous iPSC-Derived Cell Therapy Market Size Forecast by Region (2027-2032) & (\$ millions)
Table 73. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share Forecast by Region (2027-2032)
Table 74. Global Autologous iPSC-Derived Cell Therapy Market Size Forecast by Type (2027-2032) & (\$ millions)
Table 75. Global Autologous iPSC-Derived Cell Therapy Market Size Forecast by Application (2027-2032) & (\$ millions)
Table 76. Aspen Neuroscience Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors
Table 77. Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product Offered
Table 78. Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 79. Aspen Neuroscience Main Business
Table 80. Aspen Neuroscience Latest Developments
Table 81. UniXell Biotechnology Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors
Table 82. UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product Offered
Table 83. UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 84. UniXell Biotechnology Main Business
Table 85. UniXell Biotechnology Latest Developments
Table 86. Oryon Cell Therapies Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors
Table 87. Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product Offered
Table 88. Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 89. Oryon Cell Therapies Main Business
Table 90. Oryon Cell Therapies Latest Developments
Table 91. Cellio Therapeutics Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors
Table 92. Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product Offered
Table 93. Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 94. Cellio Therapeutics Main Business
Table 95. Cellio Therapeutics Latest Developments
Table 96. Cellino Details, Company Type, Autologous iPSC-Derived Cell Therapy Area

Served and Its Competitors

Table 97. Cellino Autologous iPSC-Derived Cell Therapy Product Offered

Table 98. Cellino Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 99. Cellino Main Business

Table 100. Cellino Latest Developments

Table 101. Kadis Bio Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors

Table 102. Kadis Bio Autologous iPSC-Derived Cell Therapy Product Offered

Table 103. Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 104. Kadis Bio Main Business

Table 105. Kadis Bio Latest Developments

Table 106. HeartWorks Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors

Table 107. HeartWorks Autologous iPSC-Derived Cell Therapy Product Offered

Table 108. HeartWorks Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 109. HeartWorks Main Business

Table 110. HeartWorks Latest Developments

Table 111. iCamuno Biotherapeutics Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors

Table 112. iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product Offered

Table 113. iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 114. iCamuno Biotherapeutics Main Business

Table 115. iCamuno Biotherapeutics Latest Developments

Table 116. Shize Biomedicine Details, Company Type, Autologous iPSC-Derived Cell Therapy Area Served and Its Competitors

Table 117. Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product Offered

Table 118. Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 119. Shize Biomedicine Main Business

Table 120. Shize Biomedicine Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Autologous iPSC-Derived Cell Therapy Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Autologous iPSC-Derived Cell Therapy Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Autologous iPSC-Derived Cell Therapy Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Autologous iPSC-Derived Cell Therapy Sales Market Share by Country/Region (2025)

Figure 8. Autologous iPSC-Derived Cell Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type in 2025

Figure 10. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source in 2025

Figure 11. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form in 2025

Figure 12. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage in 2025

Figure 13. Autologous iPSC-Derived Cell Therapy in Neurodegenerative Diseases

Figure 14. Global Autologous iPSC-Derived Cell Therapy Market: Neurodegenerative Diseases (2021-2026) & (\$ millions)

Figure 15. Autologous iPSC-Derived Cell Therapy in Retinal Degenerative Diseases

Figure 16. Global Autologous iPSC-Derived Cell Therapy Market: Retinal Degenerative Diseases (2021-2026) & (\$ millions)

Figure 17. Autologous iPSC-Derived Cell Therapy in Cardiovascular Ischemic Diseases

Figure 18. Global Autologous iPSC-Derived Cell Therapy Market: Cardiovascular Ischemic Diseases (2021-2026) & (\$ millions)

Figure 19. Autologous iPSC-Derived Cell Therapy in Metabolic and Endocrine Diseases

Figure 20. Global Autologous iPSC-Derived Cell Therapy Market: Metabolic and Endocrine Diseases (2021-2026) & (\$ millions)

Figure 21. Autologous iPSC-Derived Cell Therapy in Immune and Inflammatory Diseases

Figure 22. Global Autologous iPSC-Derived Cell Therapy Market: Immune and

Inflammatory Diseases (2021-2026) & (\$ millions)

Figure 23. Autologous iPSC-Derived Cell Therapy in Other Regenerative Applications

Figure 24. Global Autologous iPSC-Derived Cell Therapy Market: Other Regenerative Applications (2021-2026) & (\$ millions)

Figure 25. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application in 2025

Figure 26. Global Autologous iPSC-Derived Cell Therapy Revenue Market Share by Player in 2025

Figure 27. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share by Region (2021-2026)

Figure 28. Americas Autologous iPSC-Derived Cell Therapy Market Size 2021-2026 (\$ millions)

Figure 29. APAC Autologous iPSC-Derived Cell Therapy Market Size 2021-2026 (\$ millions)

Figure 30. Europe Autologous iPSC-Derived Cell Therapy Market Size 2021-2026 (\$ millions)

Figure 31. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size 2021-2026 (\$ millions)

Figure 32. Americas Autologous iPSC-Derived Cell Therapy Value Market Share by Country in 2025

Figure 33. United States Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026 (\$ millions)

Figure 34. Canada Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026 (\$ millions)

Figure 35. Mexico Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026 (\$ millions)

Figure 36. Brazil Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026 (\$ millions)

Figure 37. APAC Autologous iPSC-Derived Cell Therapy Market Size Market Share by Region in 2025

Figure 38. APAC Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2026)

Figure 39. APAC Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2026)

Figure 40. China Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026 (\$ millions)

Figure 41. Japan Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026 (\$ millions)

Figure 42. South Korea Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 43. Southeast Asia Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 44. India Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026

(\$ millions)

Figure 45. Australia Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 46. Europe Autologous iPSC-Derived Cell Therapy Market Size Market Share by Country in 2025

Figure 47. Europe Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2026)

Figure 48. Europe Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2026)

Figure 49. Germany Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 50. France Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 51. UK Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026

(\$ millions)

Figure 52. Italy Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026

(\$ millions)

Figure 53. Russia Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 54. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size Market Share by Region (2021-2026)

Figure 55. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2026)

Figure 56. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2026)

Figure 57. Egypt Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 58. South Africa Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 59. Israel Autologous iPSC-Derived Cell Therapy Market Size Growth 2021-2026

(\$ millions)

Figure 60. Turkey Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 61. GCC Countries Autologous iPSC-Derived Cell Therapy Market Size Growth

2021-2026 (\$ millions)

Figure 62. Americas Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 63. APAC Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 64. Europe Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 65. Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 66. United States Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 67. Canada Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 68. Mexico Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 69. Brazil Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 70. China Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 71. Japan Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 72. Korea Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 73. Southeast Asia Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 74. India Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 75. Australia Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 76. Germany Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 77. France Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 78. UK Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 79. Italy Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 80. Russia Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 81. Egypt Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$

millions)

Figure 82. South Africa Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 83. Israel Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 84. Turkey Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

Figure 85. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share Forecast by Type (2027-2032)

Figure 86. Global Autologous iPSC-Derived Cell Therapy Market Size Market Share Forecast by Application (2027-2032)

Figure 87. GCC Countries Autologous iPSC-Derived Cell Therapy Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Autologous iPSC-Derived Cell Therapy Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/GDAF0B398D3AEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDAF0B398D3AEN.html>